TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
TCT 2024 - TCTMD.com
WEBTCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
News | tctmd.com
WEBCellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction. Positive changes in prognostic biomarkers including infarct size, left ventricular dimensions and NT-proBNP level support the anti-remodeling effect of ProtheraCytes cell therapy in post-myocardial infarction patients at risk of ...
Slides | tctmd.com
WEBApr 8, 2024 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
Welcome to TCTMD | tctmd.com
WEBOn behalf of CRF and TCTMD, we would like to extend a warm welcome to our community, which has developed over the past 20 years around a common goal to improve the survival and quality of life for people living with cardiovascular disease through research and education. We look forward to seeing you at our conferences and to working together to ...
Welcome to Your Gold Account - TCTMD.com
WEBWe are very pleased to welcome you to your premium TCTMD account. As a premium member you have access to enhanced content including live video streams of conferences for Platinum members, and archives of live cases and presentations from numerous meetings throughout the year for Gold (and Platinum) members. Should you …
Conferences | tctmd.com
WEBMay 17, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
New Cholesterol Guidelines Make Room for Non-Statin Therapy …
WEBNov 10, 2018 · If treatment is started, the goal is to reduce LDL levels by 30% or more. If the patient’s 10-year risk exceeds 20%, then reduce LDL cholesterol levels by 50% or more, according to the guidelines. In primary prevention, the ACC/AHA finally open the door to using CAC screening to help guide treatment decisions (class IIa indication). For those ...
TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without …
WEBSep 26, 2019 · SAN FRANCISCO, CA (UPDATED)—Dropping aspirin after 3 months of dual antiplatelet therapy (DAPT) with ticagrelor (Brilinta, AstraZeneca) following PCI among high-risk patients is associated with lower rates of bleeding but no increased risk of death, MI, or stroke, according to results of the double-blind, placebo-controlled TWILIGHT trial.
High-Sensitivity Troponin Testing on the Rise in the US but Still ...
WEBNov 4, 2022 · By Michael O'Riordan. CHICAGO, IL—Just one in three US hospitals are currently using high-sensitivity cardiac troponin (hs-cTn) assays, although that number appears to be on the rise, according to results of a new study. The use of hs-cTn assays was associated with more echocardiography in …
Skip to content